Walgreens Bts Aln Cm (WBA) 82.33 $WBA Rite Aid to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Walgreens Bts Aln Cm (WBA) 82.33 $WBA

Rite Aid to Release Fourth Quarter Results on April 7
Business Wire - Thu Mar 24, 3:15PM CDT
Rite Aid Corporation (NYSE: RAD) said today that it will release financial results for its Fiscal 2016 Fourth Quarter at 7 a.m. Eastern time Thursday, April 7, 2016. Given the company's pending merger with Walgreens Boots Alliance, Inc. (Nasdaq: WBA), Rite Aid will not be holding a conference call. The text of the earnings release, along with the corresponding charts and supplemental information slides, will be made available immediately after the release in the Investor Relations section of the company's website at www.riteaid.com.
WBA: 82.33 (-0.01), RAD: 8.07 (+0.07)

Conn's (CONN) to Report Q4 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:40AM CDT
Conn's Inc. (CONN) is slated to report its fourth-quarter fiscal 2016 results on Mar 29.
WBA: 82.33 (-0.01), CONN: 15.82 (-0.32), OLLI: 22.01 (-0.67), STZ: 149.90 (-0.21)

Walgreens Flu Index(TM) for Week of March 20, 2016
Business Wire - Thu Mar 24, 8:00AM CDT
The Walgreens Flu Index(TM) is a weekly report developed to provide state- and market-specific information regarding flu activity, and ranking of those experiencing the highest incidences of influenza across the country.
WBA: 82.33 (-0.01)

What's in Store for Pacific Sunwear (PSUN) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 8:00AM CDT
Anaheim, CA-based specialty retailer, Pacific Sunwear of California Inc. (PSUN), is expected to report fourth-quarter fiscal 2015 results on Mar 23.
WBA: 82.33 (-0.01), PSUN: 0.12 (unch), GME: 30.27 (-0.10), STZ: 149.90 (-0.21)

Walgreens Buys AmerisourceBergen Shares per Warrants
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 4:24PM CDT
Walgreens Boots Alliance, Inc. (WBA) announced that it has exercised warrants to purchase 22.7 million shares of AmerisourceBergen Corp. (ABC) for approximately $1.17 billion.
ABC: 86.17 (-1.10), WBA: 82.33 (-0.01), ARQL: 1.63 (+0.06), CORT: 4.29 (+0.10)

This Was the Best Performing Healthcare ETF Last Week
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 19, 10:30PM CDT
IMAGE CREDIT: TBIT ON PIXABAY. It was a good week to have money in the markets, as the  S&P 500  inched 0.80% higher during the past few trading days. The famous index has now fully recovered from its horrendous start to the year and has...
IHF: 119.69 (-0.53), WBA: 82.33 (-0.01), DVA: 71.55 (-0.77), UNH: 128.59 (-1.20)

Outsourcer Genpact Rebuilds In GE’s Shrinking Shadow
at Investor's Business Daily - Fri Mar 18, 2:38PM CDT
Genpact (G) has made its mark helping companies operate more efficiently, but over the last two years the business processing firm has invested heavily to make its own firm run more effectively. The company, once an India-based arm of General...
BMO: 58.80 (-0.72), EXLS: 49.55 (-0.05), GE: 31.11 (+0.04), MDLZ: 39.51 (-0.43), G: 26.35 (unch), HON: 111.32 (-0.89), KMB: 133.55 (-0.43), INFY: 18.81 (+0.15), BA: 132.12 (-0.74), WNS: 29.85 (+0.33), WBA: 82.33 (-0.01), WIT: 12.40 (+0.09), AZN: 28.00 (-0.01), ACN: 114.30 (+6.64), CTSH: 60.32 (+1.26)

What Investors Are Saying About Valeant Pharmaceuticals (VRX)
Andrew Steele - Zacks Investment Research - Fri Mar 18, 1:38PM CDT
Valeant Pharmaceuticals stock is down to a 52-week-low essentially. Check out what investors are saying about the matter.
VRX: 31.09 (-2.34), WBA: 82.33 (-0.01)

Walgreens spends nearly $1.2 B on AmerisourceBergen shares
By The Associated Press - AP - Fri Mar 18, 11:06AM CDT
Walgreens is spending nearly $1.2 billion to build its stake in AmerisourceBergen, the pharmaceutical wholesaler that supplies its drugstores, mail order and specialty pharmaceutical businesses.
ABC: 86.17 (-1.10), WBA: 82.33 (-0.01), RAD: 8.07 (+0.07)

Walgreens Boots Alliance Exercises Warrants to Purchase AmerisourceBergen Shares
Business Wire - Fri Mar 18, 9:13AM CDT
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has exercised warrants to purchase 22,696,912 shares of AmerisourceBergen Corporation (NYSE: ABC) common stock for an aggregate payment of approximately $1.17 billion. The transaction was funded using existing cash on hand.
ABC: 86.17 (-1.10), WBA: 82.33 (-0.01)

Valeant Pharmaceuticals (VRX) in Focus after Epic Decline
Zacks Equity Research - Zacks Investment Research - Thu Mar 17, 3:20PM CDT
Valeant Pharmaceuticals International, Inc. (VRX) found itself in troubled waters again with the release of dismal preliminary fourth-quarter results and a trimmed guidance for the first quarter and 2016.
VRX: 31.09 (-2.34), WBA: 82.33 (-0.01), SCMP: 10.20 (+0.06), CORT: 4.29 (+0.10)

The 2 Best Tech Stocks to Buy for Long-Term Investing
Maher Syed - Zacks Investment Research - Thu Mar 17, 11:25AM CDT
If you believe in the power of technology, you don't want to overlook these companies.
FDX: 162.65 (+0.02), AMZN: 582.95 (+13.32), WBA: 82.33 (-0.01), FB: 113.05 (+0.51), ATSG: 14.42 (+0.11), SNE: 25.47 (-0.10), GOOGL: 754.84 (-2.72), INTC: 31.88 (-0.12), SHLD: 15.00 (+0.04), UPS: 105.43 (+0.55)

OptumRx and Walgreens Partner to Improve Consumer Convenience, Cost Savings and Outcomes
Business Wire - Thu Mar 17, 7:00AM CDT
--Integrating OptumRx's pharmacy care services solutions with Walgreens leading drugstore services will help reduce pharmacy costs and improve health outcomes
WBA: 82.33 (-0.01), UNH: 128.59 (-1.20)

Valeant Trims View, Likely to Face Credit Default; Shares Fall
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 4:42PM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) plunged 51.5% after the company announced preliminary results for the fourth quarter of 2015 and slashed its outlook for 2016.
VRX: 31.09 (-2.34), WBA: 82.33 (-0.01), CORT: 4.29 (+0.10)

Walgreens and The Leukemia & Lymphoma Society Create New Approach to Support Cancer Patients in their Communities
PR Newswire - Wed Mar 16, 2:45PM CDT
The Leukemia & Lymphoma Society (LLS) and Walgreen Co. today announced the launch of an innovative collaboration designed to further advance cancer therapies and address the changing treatment model facing patients with blood and other cancers. The collaboration, between LLS and Walgreens Specialty Pharmacy, builds on the heritage of Walgreens in serving its communities, and the 66-year history of LLS, which has invested more than $1 billion in research to advance blood cancer treatments and cures.
WBA: 82.33 (-0.01)

Is Valeant a "Bad News Buy"?
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 16, 2:02PM CDT
CEO Pearson faces a host of challenges this year. Valeant Pharmaceuticals is under the gun to address a slate of difficult problems threatening it, and it's not clear when management will be able to say its struggles are truly behind it. Can...
VRX: 31.09 (-2.34), WBA: 82.33 (-0.01)

Why Walgreens Boots (WBA) Should Be in Your Portfolio Now
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 1:30PM CDT
Currently, Walgreens Boots (WBA) is focused on the proposed takeover of the U.S. retail pharmacy chain ??? Rite Aid ??? for $17.2 billion.
WBA: 82.33 (-0.01), OFIX: 40.65 (-0.27), HRC: 48.48 (-0.12), OSUR: 6.85 (+0.03)

This Dividend Aristocrat Is Cementing Its Global Conquest of the Booming Pharmacy Industry
at The Street - Wed Mar 16, 1:19PM CDT
Drug markers are taking it on the chin as political pressure mounts on high drug prices, but that's all to the benefit of the world's biggest (and growing) pharmacy chain.
VRX: 31.09 (-2.34), WBA: 82.33 (-0.01)

Walgreens Boots Alliance (WBA) Stock Initiated With 'Outperform' Rating at Credit Suisse
at The Street - Wed Mar 16, 8:43AM CDT
Walgreens Boots Alliance (WBA) stock was initiated with an 'outperform' rating at Credit Suisse, which said the firm is still skeptical of the company's long-term growth prospects.
WBA: 82.33 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CME Group Smashes FX Open Interest Record Again

Updated Category News Views 4

Shattering Records: CME Group's Latest Milestone Well, here's a juicy nugget for your investment playbook. On September 4, 2026, CME Group proved, once again, why they're the big dog in the derivatives yard, announcing a new record in FX open interest—4,410,167 contracts! This tops the previous mark of 4,269,622 contracts set just a few months back. The futures and...

Continue Reading
Coastal Property Realities: A Deep Dive into Ownership

Updated Category News Views 4

Buying Coastal Property: A Balancing Act Ah, the dream of owning a piece of the beach in sunny South Florida. It sounds glamorous—something to brag about at the next family gathering. But let me tell you, diving into coastal property ownership isn't just about sipping cocktails by the ocean. It's about handling a fair share of headaches most folks don't anticipate....

Continue Reading
York Space Systems Faces Investor Lawsuit Over Claims

Updated Category News Views 1

Allegations Stir the Pot: York Space Systems Under Fire Now we're sailing into choppy waters with York Space Systems (YSS). There's a full-blown ruckus stirring as investors take aim at the company, thanks to a class action lawsuit alleging securities fraud. The legal beagles from Glancy Prongay Wolke & Rotter LLP are spearheading this effort, claiming that York pulled...

Continue Reading
Dentsply Sirona Faces Insider Troubles: An Investor Call

Updated Category News Views 3

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Continue Reading
Hims & Hers Health Hit by FTC Claims and Class Action

Updated Category News Views 3

Hims Faces Harsh Lessons With FTC Lawsuit There's trouble brewing in the world of telehealth, and Hims & Hers Health (NYSE: HIMS) is right at the eye of the storm. They've gone from a darling of digital health to a pariah faster than you can say 'data breach.' On July 29, 2026, they took a hit so hard you’d think the company stepped into the ring with a heavyweight...

Continue Reading
GBC 2026 Wraps Up: Korea Eyes Bio Industry Leadership

Updated Category News Views 3

GBC 2026: Korea's Giant Leap in Bio Innovation Well, there wasn't a dull moment at the 'Global Bio Conference 2026' in Seoul. Picture a melting pot where 5,600 participants from 19 countries converged to chat about the latest and greatest in biopharma innovation and regulatory strategies. That's not a setup you see every day, mind you. This event packed the room with...

Continue Reading
Lyon Biennale 2026: Art, Dreams, and Lyon's Magic

Updated Category News Views 3

Unveiling the Art Spectacle in Lyon Alright, buckle up folks, because the 18th Lyon Biennale – Contemporary Art is about to take the stage in grand fashion. Starting on the 19th of September, this art fiesta is not just any exhibit; it's an eleven-venue citywide takeover that runs until the 13th of December, and it is poised to shake up the art scene like a good splash...

Continue Reading
U.S. Court Ruling Opens Market for Cocrystal's CrysQnol™

Updated Category News Views 9

Legal Drama Clears Market Path Well, folks, here’s a win from the trenches for Cocrystal Tech that can shake up the nutraceutical market. Kaneka's grip on the patent for their ubiquinol concoctions just got busted by the U.S. District Court. They ruled that Kaneka's claims lacked utility and enablement, essentially saying they were pitching an untested hypothesis as an...

Continue Reading
Tech Breakthroughs in Cancer and Space Energy Aired

Updated Category News Views 3

Science and Technology at the Forefront Saturday nights usually have folks kicking back with some reality shows or maybe cheering on their favorite sports team. But this September 12, savvy viewers have a chance to dive deep into the guts of cutting-edge science and tech on Bloomberg Television. We're talking about 'Advancements with Ted Danson'—where science isn’t...

Continue Reading
Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 2

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading

Top 5 Most Recently Viewed Articles

Breakthrough Gene Therapy Study Offers Hope for Danon Disease

Updated Category News Views 110

Revolutionary Advances in Gene Therapy for Danon Disease Recent findings from groundbreaking research at Children's Hospital of Philadelphia reveal a promising new approach in tackling Danon disease, a complex genetic disorder predominantly affecting young males. The study not only highlights the potential of gene therapy—specifically a novel treatment known as...

Continue Reading
Biohaven Doses First Patient with Innovative BHV-8100

Updated Category News Views 4

Biohaven Breaks New Ground with BHV-8100 There’s a fresh buzz in the biopharma world as Biohaven Ltd. kicks off first-in-human dosing for their novel drug, BHV-8100. This is no small feat, and it could potentially shake up the landscape of treatments for systemic and central nervous system disorders. You know there’s weight behind a drug when it’s aiming for those...

Continue Reading
Nasdaq Sets Date for 2026 Investor Day Event

Updated Category News Views 372

Exciting Announcement from Nasdaq Nasdaq recently shared significant news regarding its upcoming 2026 Investor Day. Scheduled for the morning of February 25, 2026, this highly anticipated event will take place at the Nasdaq Global Headquarters in Times Square. This annual gathering is essential for investors as it provides insights into the company's strategic direction...

Continue Reading
Acreage Holdings Restructures Debt Agreement for Growth

Updated Category News Views 89

Acreage Holdings Restructures Debt Agreement with Canopy USA Acreage Holdings (OTC: ACRGF), Inc. is a diversified cannabis company, recently announced a strategic amendment to its debt agreement with Canopy USA, LLC, which impacts the payment terms of its outstanding obligations. This pivotal financial maneuver came into effect recently and is a reflection of the...

Continue Reading
Chlorella Market Projected Growth and Nutritional Benefits

Updated Category News Views 233

Understanding the Growth of the Chlorella Market Chlorella occupies an important place in the sphere of superfoods. This vibrant freshwater alga, famous for its rich nutritional profile, plays a vital role in the health and wellness trend that is sweeping across the globe. It is known for its presence in pills, powders, capsules, and liquid extracts, marking its...

Continue Reading